Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OMONTYS vs ARANESP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.
Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.
Anemia due to chronic kidney disease (CKD) in adults on dialysis and not on dialysis
Treatment of anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis.,Treatment of anemia due to concomitant myelosuppressive chemotherapy in patients with non-myeloid malignancies.
45 mg subcutaneously once every 4 weeks (monthly) in adults.
Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.
Terminal elimination half-life is approximately 14.5 hours in healthy adults; in hemodialysis patients, half-life is extended to 26.4–29.9 hours, supporting weekly dosing.
The terminal elimination half-life is approximately 21 hours (range 15-30 hours) in patients with chronic kidney disease following intravenous administration, and 49 hours (range 27-89 hours) after subcutaneous administration. The long half-life allows for less frequent dosing compared to epoetin alfa.
Not metabolized by cytochrome P450 enzymes; degraded into small peptides and amino acids via catabolic pathways.
Darbepoetin alfa is a recombinant protein. Its metabolism is not fully characterized but is expected to undergo proteolytic degradation into small peptides and amino acids. No specific metabolic pathways or enzymes have been identified.
Primarily eliminated via the reticuloendothelial system; no significant renal or biliary excretion. The iron component is incorporated into hemoglobin or stored as ferritin/hemosiderin.
Renal clearance accounts for approximately 10% of total body clearance; however, darbepoetin alfa is primarily eliminated via receptor-mediated endocytosis and subsequent intracellular degradation. Less than 5% is excreted unchanged in urine.
Ferric pyrophosphate citrate moiety: <5% bound to plasma proteins; iron is rapidly transferred to transferrin.
Approximately 50% bound to plasma proteins, primarily to albumin.
Vd approximately 0.47 L/kg (range 0.2–0.8 L/kg), indicating distribution primarily into plasma and interstitial fluid; iron distributes to bone marrow and reticuloendothelial system.
Vd is approximately 0.07 L/kg (range 0.04-0.10 L/kg), indicating limited distribution predominantly within the vascular and extracellular fluid compartments.
Not applicable; OMONTYS is administered only intravenously. Oral bioavailability is not relevant.
Subcutaneous: Approximately 37% (range 30-50%) relative to intravenous administration.
No dosage adjustment required for any degree of renal impairment, including end-stage renal disease.
No dose adjustment recommended for GFR ≥60 m L/min/1.73 m2; for GFR <60 m L/min/1.73 m2, no adjustment needed as drug is not renally eliminated, but monitor hemoglobin closely.
No dosage adjustment recommended for mild or moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C).
No specific Child-Pugh dose adjustments; use with caution in severe hepatic impairment due to limited data.
Safety and efficacy in pediatric patients have not been established; no recommended dose.
For pediatric patients (≥1 year) on dialysis: starting dose 0.45 mcg/kg intravenously or subcutaneously once weekly; adjust to maintain hemoglobin target of 9-10.5 g/d L.
No specific dosage adjustment needed; consider age-related renal function and individual tolerability.
No specific dose adjustment; use lowest effective dose to avoid excessive hemoglobin levels (risk of thromboembolic events).
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality when targeting hemoglobin levels >11 g/d L; increased risk of tumor progression and recurrence in patients with cancer; not indicated for treatment of anemia in cancer patients due to increased risk of death and serious cardiovascular events.
WARNING: INCREASED RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS, AND TUMOR PROGRESSION OR RECURRENCE. Use the lowest dose sufficient to avoid red blood cell transfusion. ESAs increased the risk of death and serious cardiovascular events in clinical trials when targeting hemoglobin levels >11 g/d L. ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. To decrease these risks, use the lowest dose needed to avoid red blood cell transfusions.
Increased mortality, serious cardiovascular events, and thromboembolic events; hypertension; seizures; pure red cell aplasia (PRCA) with neutralizing antibodies; increased risk of tumor progression in cancer patients; hemoglobin monitoring; iron deficiency management; hypersensitivity reactions including anaphylaxis.
Increased mortality, serious cardiovascular events, and thromboembolic events when targeting hemoglobin >11 g/d L.,Increased risk of tumor progression or recurrence in cancer patients.,Hypertension: monitor blood pressure closely; treat adequately.,Seizures: increased risk in patients with CKD.,Pure red cell aplasia (PRCA) and severe anemia with neutralizing antibodies to erythropoietin; discontinue if suspected.,Risk of serious allergic reactions including anaphylaxis.,Increased risk of thrombotic events including venous thromboembolism and vascular access thrombosis.,Monitor hemoglobin weekly until stable, then periodically.
Uncontrolled hypertension; history of pure red cell aplasia (PRCA) following erythropoiesis-stimulating agents; known hypersensitivity to OMONTYS or any of its components.
Uncontrolled hypertension.,History of serious allergic reactions to darbepoetin alfa or any product components.,Pure red cell aplasia (PRCA) following erythropoietin therapy.
No clinically significant food interactions reported. Administer subcutaneously, independent of meals.
No known food interactions. Avoid alcohol due to potential interference with erythropoiesis and iron metabolism. Maintain adequate dietary intake of iron, vitamin B12, and folate.
OMONTYS (pegcetacoplan) is a complement inhibitor. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental effects were observed at maternal exposures up to 20 times the human exposure at the recommended clinical dose. Based on its mechanism of action as a complement inhibitor, there is a theoretical risk of increased susceptibility to infections for the fetus, but no specific teratogenic effects have been identified. The drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Animal studies show no evidence of teratogenicity in rats and rabbits at doses up to 150 mcg/kg. No adequate human studies in pregnancy. Use only if potential benefit justifies potential risk to fetus.
It is unknown whether pegcetacoplan is excreted in human milk, affects the breastfed infant, or affects milk production. No data on the milk-to-plasma (M/P) ratio are available. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Unknown if excreted in human milk; M/P ratio not determined. Weigh benefits against potential risks to infant.
No specific pharmacokinetic studies have been conducted in pregnant women. Based on the drug's large molecular weight and subcutaneous route, significant alterations in clearance due to pregnancy-induced physiological changes (e.g., increased blood volume, renal clearance) are possible but not quantified. The recommended dose for non-pregnant adults is 1080 mg subcutaneously twice weekly. No formal dose adjustment is recommended during pregnancy due to lack of data; however, close monitoring for clinical efficacy and safety is advised. Dose adjustments should be guided by therapeutic response and tolerability.
No specific dose adjustments recommended based on pharmacokinetic changes; dosing should be individualized based on hemoglobin response and iron status.
OMONTYS (pegcetacoplan) is a C3 inhibitor approved for paroxysmal nocturnal hemoglobinuria (PNH). Initiate only in patients vaccinated against encapsulated bacteria (Neisseria meningitidis, Streptococcus pneumoniae, Haemophilus influenzae type b) due to increased infection risk. Monitor for hemolysis, thrombosis, and breakthrough disease; consider dose adjustments if hemoglobin drops significantly. Do not discontinue abruptly—switch to alternative therapy under medical supervision.
Darbepoetin alfa has a longer half-life than epoetin alfa, allowing for less frequent dosing (every 1-2 weeks vs. 1-3 times weekly). Monitor hemoglobin weekly until stable, then monthly; target Hb 10-12 g/d L. Do not use to treat anemia of chronic disease or cancer-related anemia in patients not receiving chemotherapy. Increased risk of thrombosis, especially if Hb exceeds 12 g/d L. Pure red cell aplasia (PRCA) can occur with neutralizing antibodies; discontinue and do not switch to another erythropoiesis-stimulating agent. Ensure adequate iron stores (ferritin >100 ng/m L, TSAT >20%) before and during therapy.
You must receive vaccinations against meningococcus, pneumococcus, and Haemophilus influenzae type b before starting OMONTYS and maintain up-to-date immunizations.,Report any signs of infection immediately: fever, headache with stiff neck, confusion, chills, or rash.,Do not stop taking OMONTYS without talking to your doctor—sudden discontinuation may cause serious hemolysis.,You may experience injection site reactions; rotate injection sites and avoid injecting into tender or scarred areas.,Store OMONTYS in the refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze or shake. Protect from light.
This medication helps your body make more red blood cells to treat anemia.,It is given as an injection under the skin or into a vein, usually once every 1 to 2 weeks.,Do not shake the vial; store it in the refrigerator and protect from light.,Report symptoms of blood clots such as leg pain, chest pain, sudden shortness of breath, or vision changes.,You will need regular blood tests to check your hemoglobin levels and iron stores.,Do not use this medicine if you have high blood pressure that is not well controlled.,Take iron supplements as prescribed to help the medicine work effectively.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OMONTYS vs ARANESP, answered by our medical review team.
OMONTYS is a Erythropoiesis-Stimulating Agent that works by Erythropoiesis-stimulating agent; synthetic peptide agonist of the erythropoietin receptor (EPOR) that stimulates erythropoiesis in red blood cell precursors.. ARANESP is a Erythropoiesis-Stimulating Agent that works by Aranesp (darbepoetin alfa) is an erythropoiesis-stimulating agent (ESA) that stimulates erythropoiesis by binding to the erythropoietin receptor on erythroid progenitor cells, promoting their survival, proliferation, and differentiation into mature red blood cells.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OMONTYS and ARANESP depend on the specific clinical indication. These are both Erythropoiesis-Stimulating Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OMONTYS is: 45 mg subcutaneously once every 4 weeks (monthly) in adults.. The standard adult dose of ARANESP is: Initial dose 0.45 mcg/kg intravenously or subcutaneously once weekly; for patients converting from epoetin alfa, see prescribing information for dose conversion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OMONTYS and ARANESP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OMONTYS is classified as Category C. OMONTYS (pegcetacoplan) is a complement inhibitor. There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, no adverse developmental eff. ARANESP is classified as Category C. Animal studies show no evidence of teratogenicity in rats and rabbits at doses up to 150 mcg/kg. No adequate human studies in pregnancy. Use only if potential benefit justifies pot. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.